699 8th Street
Suite 600
San Francisco, CA 94103
United States
415 632 5700
https://www.irhythmtech.com
Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 1,793
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Quentin S. Blackford | President, CEO & Director | 2.15M | N/A | 1979 |
Mr. Brice Bobzien CPA | Chief Financial Officer | 685.12k | N/A | 1979 |
Dr. Minang P. Turakhia M.D., M.S. | Chief Medical & Scientific Officer and Executive VP of Product Innovation | 1M | N/A | 1974 |
Mr. Patrick Michael Murphy J.D. | Chief Business & Legal Officer | 1.28M | N/A | 1979 |
Mr. Douglas J. Devine | Executive Advisor | 800k | N/A | 1970 |
Mr. Chad M. Patterson | Chief Commercial Officer | 771.51k | N/A | 1982 |
Mr. Marc Rosenbaum | Senior VP of Finance & Chief Accounting Officer | N/A | N/A | 1972 |
Mr. Mark J. Day Ph.D. | Chief Technology Officer | 718.76k | 1.28M | 1971 |
Mr. Daniel G. Wilson | Executive VP of Corporate Development & Investor Relations | 670.09k | N/A | 1983 |
Ms. Sumi Shrishrimal | Executive VP & Chief Risk Officer | N/A | N/A | 1979 |
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
iRhythm Technologies, Inc.’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder rights: 6; Compensation: 7.